Adial Pharmaceuticals, Inc. (ADIL)

US — Healthcare Sector

Peers: RNAZ ADTX RVPH ATXI AMTI CBIO ALRN BPTH BNTC HOTH REVB NRBO VRAX RNXT AXLA BTTX KTTA ONTX DFFN AEZS TNXP

Automate Your Wheel Strategy on ADIL

With Tiblio's Option Bot, you can configure your own wheel strategy including ADIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol ADIL
Rev/Share 0.0
Book/Share 0.1144
PB 2.145
Debt/Equity 0.0
CurrentRatio 1.9851
ROIC -4.0941

MktCap 2560675.0
FreeCF/Share -0.3702
PFCF -0.3721
PE -0.5097
Debt/Assets 0.0
DivYield 0
ROE -2.1888

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 4
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

ADIL
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), and Series C Warrants (the "Series C Warrants", and together with the Series B …

image for news Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

ADIL
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use

image for news Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

ADIL
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval

image for news Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

ADIL
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders

image for news Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

About Adial Pharmaceuticals, Inc. (ADIL)

IPO Date 2018-07-27
Website https://www.adialpharma.com
Industry Biotechnology
CEO Mr. Cary John Claiborne MBA
Employees 5

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.